Table 1.
Baseline characteristics of the sample.
| Characteristics | PaperPRO group (n=14) | OITcontrol group (n=16) | P value | |||||
| Female, n (%) | 5 (36) | 10 (63) | .14 | |||||
| Age (years), mean (SD) | 6.9 (1.9) | 7.6 (3.7) | .75 | |||||
| Asthma, n (%) | 5 (36) | 7 (44) | .65 | |||||
| Previous anaphylaxis with OITa allergen, n (%) | 7 (50) | 13 (81) | .08 | |||||
| OIT with egg, n (%) | 8 (57) | 8 (50) | .70 | |||||
| OIT with milk, n (%) | 6 (43) | 8 (50) | .70 | |||||
| Antihistaminic premedication, n (%) | 0 (0) | 4 (25) | .07 | |||||
| Omalizumab premedication, n (%) | 1 (7) | 1 (6) | .92 | |||||
| Total immunoglobulin E value (kU/L), median (Q1-Q3b) | 494.5 (120-858) | 258 (87-931) | .57 | |||||
| In egg OIT patients | ||||||||
|
|
OIT with egg, n (%) | 8 (57) | 8 (50) | .70 | ||||
|
|
Specific immunoglobulin E (kUA/L), median (Q1-Q3) | |||||||
|
|
|
Egg white | 7.7 (2.2-13.8) | 9 (5.7-16.2) | .56 | |||
|
|
|
Egg yolk | 1.9 (0.5-4.4) | 3 (1.1-7.6) | .40 | |||
|
|
|
Ovalbumin | 4 (0.6-8.8) | 4.9 (1.4-9) | .67 | |||
|
|
|
Ovomucoid | 4.1 (0.5-14.1) | 8.1 (4.5-17.3) | .21 | |||
|
|
Prick test diameter (mm), median (Q1-Q3) | |||||||
|
|
|
Egg white | 7 (3-9.7) | 8 (6.5-11) | .46 | |||
|
|
|
Egg yolk | 5 (2.2-7.5) | 6.5 (3-8) | .67 | |||
|
|
|
Ovalbumin | 6.2 (2.7-10) | 9 (6-10) | .53 | |||
|
|
|
Ovomucoid | 5.5 (4.2-9.7) | 9.5 (7-15) | .19 | |||
| In milk OIT patients | ||||||||
|
|
OIT with milk, n (%) | 6 (43) | 8 (50) | .70 | ||||
|
|
Specific immunoglobulin E (kUA/L), median (Q1-Q3) | |||||||
|
|
|
Milk | 5.9 (3.9-7.8) | 8.6 (3.8-19.8) | .70 | |||
|
|
|
Alpha-lactalbumin | 1.1 (0.4-3.2) | 0.4 (0.1-9.8) | .30 | |||
|
|
|
Beta-lactoglobulin | 0.7 (0.4-1.4) | 0.5 (0.2-0.9) | .52 | |||
|
|
|
Casein | 3.7 (1.6-9.4) | 2.8 (0.8-13.6) | .56 | |||
|
|
Prick test diameter (mm), median (Q1-Q3) | |||||||
|
|
|
Milk | 4.7 (3-5) | 4.7 (3.5-10.2) | .56 | |||
|
|
|
Alpha-lactalbumin | 5.5 (4.5-6) | 3 (0-7) | .49 | |||
|
|
|
Beta-lactoglobulin | 6.7 (5.5-9.5) | 7 (3.5-9.2) | .43 | |||
|
|
|
Casein | 7.5 (3-9) | 3.7 (1-12) | .56 | |||
aOIT: oral immunotherapy.
bQ1-Q3: first quartile-third quartile.